β‐Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1‐regulated Wnt/β‐catenin pathway
Journal of Cellular and Molecular Medicine · 2024-02 · 28 (3)
DOI: 10.1111/jcmm.18072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 08.12.2023. Verfasst von Yuankun Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious and Tropical Diseases, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Sitosterols. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hainan Provincial Department of Health, Major Science and Technology Projects in Anhui Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
β‐Sitosterol is a natural compound with demonstrated anti‐cancer properties against various cancers. However, its effects on hepatocellular carcinoma (HCC) and the underlying mechanisms are not well understood. This study aims to investigate the impact of β‐sitosterol on HCC. In this study, we investigated the effects of β‐sitosterol on HCC tumour growth and metastasis using a xenograft mouse model and a range of molecular analyses, including bioinformatics, real‐time PCR, western blotting, lentivirus transfection, CCK8, scratch and transwell assays. The results found that β‐sitosterol significantly inhibits HepG2 cell proliferation, migration and invasion both in vitro and in vivo. Bioinformatics analysis identifies forkhead box M1 (FOXM1) as a potential target for β‐sitosterol in HCC treatment. FOXM1 is upregulated in HCC tissues and cell lines, correlating with poor prognosis in patients. β‐Sitosterol downregulates FOXM1 expression in vitro and in vivo. FOXM1 overexpression mitigates β‐sitosterol's inhibitory effects on HepG2 cells. Additionally, β‐sitosterol suppresses epithelial–mesenchymal transition (EMT) in HepG2 cells, while FOXM1 overexpression promotes EMT. Mechanistically, β‐sitosterol inhibits Wnt/β‐catenin signalling by downregulating FOXM1, regulating target gene transcription related to HepG2 cell proliferation and metastasis. β‐Sitosterol shows promising potential as a therapeutic candidate for inhibiting HCC growth and metastasis through FOXM1 downregulation and Wnt/β‐catenin signalling inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious and Tropical Diseases, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
- Key Laboratory of Tropical Translational Medicine of Ministry of Health, Hainan Medical University, Haikou, Hainan, China.
- Department of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
- Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
ORCID-Profile: Wenting Li
Förderung
- Hainan Provincial Department of Health
- Major Science and Technology Projects in Anhui Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, Y., Yang, Y., Wang, N., Liu, R., Wu, Q., Pei, H., & Li, W. (2024). β‐Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1‐regulated Wnt/β‐catenin pathway. Journal of Cellular and Molecular Medicine, 28(3). https://doi.org/10.1111/jcmm.18072
Vancouver
Chen Y, Yang Y, Wang N, Liu R, Wu Q, Pei H, et al. β‐Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1‐regulated Wnt/β‐catenin pathway. Journal of Cellular and Molecular Medicine. 2024;28(3). doi:10.1111/jcmm.18072
BibTeX
@article{Chen2024,
author = {Chen, Yuankun and Yang, Yijun and Wang, Nengyi and Liu, Rui and Wu, Qiuping and Pei, Hua and Li, Wenting},
title = {β‐Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1‐regulated Wnt/β‐catenin pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {3},
doi = {10.1111/jcmm.18072}
}
EUVIMED